Experimental Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib or evobrutinib, are as effective as the approved therapy Aubagio (teriflunomide) at preventing relapses in people with relapsing forms of multiple sclerosis (MS), according to a review of published studies. The review found the therapies to be equally safe. BTK inhibitors are better at delaying short-term […]
The post BTK inhibitors match Aubagio at reducing relapse rates in MS: Review appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com